🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for EGFR Positive Non-small Cell Lung Cancer

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs NCT06775743Phase 21 site📍 Shanghai Fudan University · Tests: ORIENT-31 regimen, SBRT A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site📍 Jerusalem Hadassah Medical Organization · Tests: Stereotactic surgery A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT04853342Phase 31 site📍 Suzhou Allist Pharmaceuticals, Inc. · Tests: Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC NCT06109558Phase 1, Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: LMV-12(HE003) A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer NCT04951635Phase 31 site📍 Ji'nan Jiangsu Hansoh Pharmaceutical Co., Ltd. · Tests: Almonertinib, Placebo Almonertinib Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA NCT05334277Phase 226 sites📍 Changchun📍 Chengdu📍 Dongguan Sun Yat-sen University · Tests: Furmonertinib, Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression NCT06269211Phase 22 sites📍 Guangzhou📍 Shanghai Ruijin Hospital · Tests: Toripalimab Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites📍 Los Angeles📍 Grand Rapids📍 New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: GTAEXS617, SoC Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC NCT07671092EARLY Phase 16 sites📍 St Leonards📍 Nedlands📍 Perth RayzeBio, Inc. · Tests: RYZ211/212 Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC NCT06863506Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: befotertinib Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients NCT06659458n/a1 site📍 Baton Rouge Our Lady of the Lake Hospital · Tests: blood draw, Gene sequencing Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification NCT07322783Phase 21 site📍 Qingdao Qingdao Central Hospital · Tests: • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases NCT07304739Phase 23 sites📍 Cangzhou📍 Tianjin📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer NCT06304441NA1 site📍 Huizhou Guangzhou Medical University · Tests: Osimertinib, Pemetrexed Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC NCT07742332Phase 21 site📍 Shanghai Peng Zhang · Tests: Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC NCT05060796EARLY Phase 11 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy NCT07375316Phase 24 sites📍 Guangzhou📍 Meizhou📍 Shantou Guangdong Association of Clinical Trials · Tests: Osimertinib + Sacituzumab Tirumotecan, Osimertinib Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Ivonescimab Injection Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer NCT07806604n/a2 sites📍 Beijing📍 Shanghai Betta Pharmaceuticals Co., Ltd. · Tests: Icotinib, Routine Observational Osimertinib for Advanced EGFR-positive NSCLC Patients NCT05037331n/a1 site📍 Singapore National University Hospital, Singapore To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT06192849Phase 21 site📍 Chengdu Juan LI, MD · Tests: Furmonertinib A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases NCT06970639Phase 31 site📍 Guangdong Allist Pharmaceuticals, Inc. · Tests: Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection, Pemetrexed Disodium for Injection, Osim… Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer NCT06755684Phase 21 site📍 Shanghai Peng Zhang · Tests: Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) NCT05598528n/a1 site📍 Changsha Second Xiangya Hospital of Central South University · Tests: Genomic profiles detection, circulating tumor DNA detection Patient-centered, Optimal Integration of Survivorship and Palliative Care NCT04900935NA1 site📍 Boston Massachusetts General Hospital · Tests: POISE Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations NCT06041776Phase 33 sites📍 Beijing📍 Nanjing📍 Shanghai Betta Pharmaceuticals Co., Ltd. · Tests: Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC NCT06709859Phase 21 site📍 Jinan Shandong Public Health Clinical Center · Tests: Afatinib plus chemotherapy as conversion treatment APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors NCT03175224Phase 235 sites📍 Los Angeles📍 Tampa📍 Boston Apollomics Inc. · Tests: APL-101 Oral Capsules
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy